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Received June 26, 2015; accepted November 6, 2015AbstractBackground: Esophageal cancer is a highly lethal malignancy, and its treatment has undergone a major evolution over the past 15 years. The
objective of this study was to report our experience on the efficacy of definite chemoradiotherapy with the intensity-modulated radiotherapy
(IMRT) technique in treating locally advanced esophageal cancer.
Methods: From September 2004 to November 2011, 39 patients with biopsy-proven esophageal cancer, clinical stage T1-4N0-3M0 according to
the American Joint Committee on Cancer 7th edition were enrolled. In these enrolled cases, either the tumor was unresectable or the patients
refused surgery. All patients received a total radiation dose of 40e56 Gy in 20e28 fractions using IMRT planning. Five to seven radiation beam
angles were designed according to the specific shape of the clinical target volume (CTV) and were delivered by a linear accelerator with photons
of 6e10 MV energy. The gross tumor volume, CTV, planning target volume, and the organs at risk were outlined, and the homogeneity index
(HI) and the conformity index (CI) were calculated. The treatment-related toxicities were also reviewed.
Results: The mean follow-up time was 22.4 months (range, 2.0e91.0 months). The 2- and 3-year overall survival rates were 30% and 28%,
respectively. The most common Grade 3/4 toxicity was hematologic toxicity (43.6%). The IMRT plans showed high-dose homogeneity to the
target, with a calculated HI of 0.9. The calculated CI of 0.8 also showed high conformity treatment dose to target within an acceptable dose
range. For the total lungs, the average mean dose was 1313.7 cGy. The V5 and V20 of the total lungs were 67.8% and 23.4%, respectively. For
the heart, the average mean dose was 2319.2 cGy. The V30 and V35 of the heart were 30.2% and 21.5%, respectively.
Conclusion: Concurrent chemoradiotherapy using the IMRT technique for treating locally advanced unresectable esophageal cancer is feasible,
with better conformity of target volume as well as improved sparing of organs at risk.
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Esophageal cancer is a highly lethal malignancy, and its
treatment has undergone a major evolution over the past
15 years. Surgical intervention is the treatment of choice for
early stage esophageal cancer, but the 5-year survival rates
reported in a recent study were about 15e20% for surgery
alone.1 For potentially resectable locally advanced tumor
stages, trimodal treatment including neoadjuvant chemo-
radiotherapy followed by surgical resection showed bettervier Taiwan LLC. This is an open access article under the CC BY-NC-ND li-
Table 1
Patient and tumor characteristics, radiation dose, and clinical response after
treatment (n ¼ 39).
Variables n %
Sex
Women 2 5.13
Men 37 94.87
Eastern Cooperative Oncology Group performance status
1 5 12.82
2 34 87.18
Histology
Squamous cell carcinoma 38 97.44
Adenocarcinoma 1 2.56
T stage
T1 3 7.69
T2 2 5.13
T3 26 66.67
T4 8 20.51
N stage
N0 9 23.08
N1 25 64.10
N2 5 12.82
American Joint Committee on Cancer stage
<IIIA 10 25.64
IIIA 29 74.36
Chemotherapy cycles
<4 16 41.03
4 23 58.97
Tumor length (cm)
<8 25 64.10
8 14 35.90
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of these patients are not suitable for surgery due to technical,
functional, or medical reasons.2
Definitive chemoradiotherapy is an alternative treatment
option for patients who are not candidates for surgery. The
landmark trial of definite chemoradiotherapy is the Radiation
Therapy Oncology Group (RTOG) 85-01, which showed a
better 5-year survival rate than radiation alone and a projected
10-year survival rate of 20%.3,4 Locoregional recurrence is the
most common failure pattern of definite chemoradiotherapy,
but dose escalation to more than 50.4 Gy did not show any
benefit according to a report by Minsky et al.5
Radiotherapy is a major treatment component for unre-
sectable locally advanced esophageal carcinoma. Tradition-
ally, the radiation technique is arranged with an
anteroposterior/posteroanterior field, followed by the three-
field technique with an anteroposterior field plus two poste-
rior oblique fields or the four-field box technique. There have
been a number of advances in treatment planning and delivery
in radiotherapy, and the current recommended planning
method of choice is three-dimensional-conformal radiotherapy
(3D-CRT).6
The innovative technology of intensity-modulated radio-
therapy (IMRT) in radiation delivery offers improved coverage
of the target volume while reducing the doses delivered to the
surrounding normal tissues. IMRT is an advanced form of 3D-
CRT, which uses nonuniform radiation beams to maximize the
radiation dose of the target volume and simultaneously mini-
mize the radiation dose of normal tissues. The introduction of
IMRT for treating many malignancies, such as malignant
cancers of the head and neck, prostate, breast, ovary, cervix,
and lung, allowed for reduced toxicities without sacrificing
local control rate.
There are several critical organs surrounding the esophagus,
such as the lung, the heart, and the spinal cord, which makes it
difficult to achieve better local control by dose escalation
using the conventional radiation technique. The better dosi-
metric characteristics of IMRT are thought to provide a better
dosimetric profile, thereby reducing the treatment-related
toxicities when used concurrently with chemotherapy for
unresectable esophageal cancer.
In this paper, we present our experience of definite che-
moradiotherapy with the IMRT technique in treating locally
advanced esophageal cancer.
2. Methods
Tumor location
Cervical 2 5.13
Upper thoracic 8 20.512.1. Patient population and concurrent chemotherapyMiddle thoracic 18 46.15
Lower thoracic 11 28.21
Radiation dose (cGy)
5040 14 35.90
>5040 25 64.10
Clinical response after chemoradiotherapy
Complete response 23 58.97
Partial response 10 25.64
Disease progression 1 2.56
Unknown 5 1.28Between September 2004 and November 2011, 39 patients
with locally advanced esophageal cancer who received definite
chemoradiotherapy with the IMRT technique were retrospec-
tively reviewed. All patients had biopsy-proven adenocarci-
noma or squamous cell carcinoma of the esophagus. The
clinical stage screening tools included chest computed to-
mography (CT), endoscopic ultrasound, chest X-ray, bone
scan, liver sonography, and/or positron emission tomography/CT (PET/CT) scan. According to the American Joint Com-
mittee on Cancer (AJCC) TNM staging 7th edition, patients
who had clinical stage T1-4N0-3M0, had inoperable esopha-
geal cancer, or refused operation for esophageal cancer were
included in the study.
The median age was 58 years (range, 40e84 years). Most
patients were men, and nearly all patients had squamous cell
carcinoma, except one who had adenocarcinoma. The tumor
location was mainly in the middle thoracic esophagus
(46.2%), followed by the lower thoracic esophagus (28.2%).
Twenty-nine patients (74.4%) had a clinical tumor stage of
more than AJCC Stage IIIA. The details of patients' charac-
teristics are presented in Table 1.
The concurrent chemotherapy consisted of intravenous
cisplatin (20 mg/m2) for 1 hour and continuous intravenous
infusion of fluorouracil (5-FU; 800 mg/m2) for 24 hours from
Day 1 to Day 4 on Week 1 and Week 5 during radiotherapy for
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same regimen with concurrent chemotherapy every 3 weeks
for two to four cycles according to the patients' clinical con-
dition and the physician's decision.2.2. RadiotherapyThe radiotherapy treatment plan was performed accord-
ing to the protocol described in our previous study.7 The
gross tumor volume (GTV), the clinical target volume
(CTV), planning target volume (PTV), and the organs at risk
were outlined on the planning CT scan images. The GTV
was contoured by the attending radiation oncologist using
all available resources, such as PET/CT scan, endoscopic
findings, and diagnostic CT scan images. The CTV included
1.0-cm expansion of the GTV in circumferential direction,
5-cm extension of the GTV in the cephaladecaudad direc-
tion, lymph nodes at the mediastinum, supraclavicular area
(for cervical, upper, and middle thoracic esophageal tu-
mors), and celiac trunk region (for lower thoracic esopha-
geal tumor portion). A margin of 0.5 cm was added to the
CTV, given the PTV, to account for daily setup error and
organ motion. We planned to deliver a total dose of
40e56 Gy to the PTV in 20e28 fractions with or without
concomitant boost to the primary tumor within 5e6 weeks.
Dose constraint for lungs was less than 15 Gy for mean lung
dose, and for a volume under 30%, a dose of more than
20 Gy (V20) was used. Dose constraint for a heart with
volume less than 30% was 35 Gy.
Five to seven radiation beam angles were designed by an
experienced radiation oncologist according to the specific
shape of the CTV. The radiation doses were delivered by a
linear accelerator with photons of 6 MVor 10 MVenergy. The
quality of the plan was evaluated by doseevolume histogram,
dose-distribution curves, a calculated homogeneity index (HI),
and a calculated conformity index (CI). The HI was calculated
and defined as the fraction of PTV with a dose between 100%
and 112% of the prescribed dose. The CI was calculated with
modification according to the definition proposed by Baltas
et al8 for evaluating brachytherapy implants and was defined
as CI ¼ C1  C2, and C1 ¼ VCTVref/VCTV, C2 ¼ VCTVref/Vref,
where VCTVref is CTV receiving the reference dose or above,
VCTV is the volume of CTV contouring, and Vref is the body
volume receiving the reference dose or above.2.3. Toxicity assessmentAcute toxicities were divided into hematologic toxicity
(leukopenia, anemia, and thrombocytopenia) and non-
hematologic toxicity (esophagitis, radiation dermatitis, and
pneumonitis) according to the toxicity criteria of RTOG.9 All
patients were evaluated each week during the treatment and
every 2 weeks after the last chemotherapy for at least
3 months. The physical examinations and image assessment
were performed every 3e4 months for 3 years and then every
6 months for 2 years. Annual follow-up was arranged for the
following 5 years.2.4. Treatment response evaluationAll patients received either chest CT, gastroscopy plus bi-
opsy, or PET/CT scan 2e12 weeks after completion of
radiotherapy. The treatment response was recorded and was
defined as clinically complete response (CR), partial response
(PR), or disease progression (PD) according to the Response
Evaluation Criteria in Solid Tumors guidelines version 1.1.10
The clinical CR was defined as no residual tumor according
to the pathologic report of post-treatment gastroscopic biopsy,
post-treatment chest CT, and no evidence of distant metastasis
by PET/CT scan. The patients who did not have restaging
examinations mentioned above or residual tumor after con-
current chemoradiotherapy (CCRT) were classified into PR or
PD.2.5. Treatment failuresThe diagnosis of residual, recurrence, or metastasis disease
was aided by clinical examinations including physical exam-
ination, CT, esophagoscopy plus biopsy, and/or PET/CT scan.
The locoregional recurrent locations were compared with the
treatment planning and isodose curve and were divided into in-
field, marginal, and out-field failure. In- or out-field failure
was assessed based on whether the failure location was inside
or outside the PTV area. Marginal failure was defined as
outside of PTV, but less than 1 cm in circumferential direction
and 3 cm in the cephaladecaudad direction.2.6. Statistical analysisThe 1st day was defined as the start day of radiotherapy.
The survival was analyzed by the KaplaneMeier method. The
locoregional recurrence rate and distant metastasis rate were
represented by the cumulative incidence. Cox proportional
hazard models were used for the calculation of the hazard ratio
of death. The differences were considered significant when the
p values were < 0.05 by log-rank test. The data were analyzed
using SAS 9.3 statistical software (SAS Institute Inc., Cary,
NC, USA).
3. Results3.1. Clinical resultsThe mean follow-up time was 22.4 months (range,
2.0e91.0 months). For alive patients, the mean follow-up time
was 53.4 months (range, 5.04e91.0 months). The 2- and 3-
year overall survival rates were 30% and 28%, respectively
(Fig. 1). Two patients died within 1 month after radiotherapy
due to pneumonia. Six patients died between 1 month and
3 months after radiotherapy, and the main cause of death was
infection (pneumonia and sepsis). Among these eight patients,
four patients received post-CCRT restaging examinations.
Complete clinical response was found in one patient, PR in
two patients, and progression of disease in one patient. The
other four patients had developed pneumonia complicated
Fig. 1. Overall survival (OS). Fig. 3. Distant metastasis free survival rate (DMFS).
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nations were arranged.
Six patients experienced locoregional recurrence, including
local recurrence alone in one, regional lymph node recurrence
alone in four, and both in one. Of the six patients, in-field
failure was found in four, out-field failure in one, and mar-
ginal failure in one. The 2- and 3-year locoregional relapse-
free survival rates were 60% and 50%, respectively (Fig. 2).
Eight patients experienced distant metastases (2 with lung,
1 with pleural seeding, 1 to brain, 1 to bone, 1 to liver, 1 to
colon, and 1 with anterior mediastinal metastasis). Both the 2-
and 3-year distant metastasis-free survival rates were 50%
(Fig. 3).
Among all patients, 23 and 10 patients achieved CR and
PR, respectively. One patient had PD, and the outcome in five
patients was unknown. The overall response rate (CR and PR)
was 84.6%.
Of the 23 patients who reached clinical CR, five patients
(22%) experienced distant metastasis, six patients (26%)
experienced locoregional relapse, and one experienced both.Fig. 2. Locoregional relapse-free survival rate (LRFS).3.2. Treatment-related toxicities and complianceTwenty-five patients had radiation dose of over 50.4 Gy,
three patients received < 50 Gy, and 11 patients received be-
tween 50 Gy and 50.4 Gy. Twenty-three patients could tolerate
chemotherapy for at least four cycles. All three patients with a
radiation dose less than 50 Gy received concurrent chemo-
therapy for two cycles. The details of treatment-related tox-
icities are presented in Table 2.
The most common Grade 3/4 toxicity was hematologic
toxicity (43.6%). Only one patient had Grade 4 non-
hematologic toxicity (radiation dermatitis). No Grade 3/4
esophagitis or pneumonitis was found.3.3. Dosimetric resultsDosimetric analysis was performed for 39 patients; the
details of dose data are presented in Table 3. The IMRT plans
showed high-dose homogeneity to the target, with a calculated
HI of 0.9. The calculated CI of 0.8 also showed high confor-
mity treatment dose to target within an acceptable dose range.
For the total lungs, the average mean dose was 1313.7 cGy.Table 2
Treatment-related toxicities (n ¼ 39).
n %
Hematology
Grade 0 4 10.26
Grade 1 5 12.82
Grade 2 13 33.33
Grade 3 9 23.08
Grade 4 8 20.51
Nonhematology
Grade 0 6 15.38
Grade 1 8 20.51
Grade 2 24 61.54
Grade 3 0 0
Grade 4 1 2.56
Table 3
Dosimetric results (n ¼ 39).
Mean Standard
deviation
Median Minimum Maximum
GTV (mL) 86.04 97.20 55.30 0.00 479.50
GTV mean (cGy) 5431.79 933.09 5480.40 0.00 6054.10
CTV (mL) 418.83 198.88 374.20 73.90 1036.70
CTV mean (cGy) 5421.44 126.79 5399.40 5180.50 5739.90
PTV minimal dose (cGy) 4877.92 142.87 4912.50 4382.50 5119.50
PTV maximal dose (cGy) 5762.04 372.31 5746.10 3938.50 6221.50
PTV volume (mL) 645.42 264.54 598.00 268.60 1371.90
PTV reference (%) 0.97 0.02 0.97 0.89 1.00
Body reference (mL) 747.73 288.21 714.30 162.60 1546.90
Conformity index 0.80 0.05 0.80 0.68 0.92
Homogeneity index 0.90 0.08 0.91 0.71 1.00
Total lung V5 (%) 67.80 17.60 70.40 21.60 93.50
Total lung V20 (%) 23.41 7.77 24.90 8.80 42.70
Total lung mean (cGy) 1313.73 346.79 1319.70 579.80 2046.00
Heart V35 (%) 21.53 15.87 17.50 0.00 73.00
Heart V30 (%) 30.17 19.05 27.20 0.00 87.40
Heart mean (cGy) 2319.22 937.74 2527.20 67.00 4158.90
CTV ¼ clinical target volume; GTV ¼ gross tumor volume; PTV ¼ planning
target volume.
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respectively. For the heart, the average mean dose was
2319.2 cGy. The V30 and V35 of the heart were 30.2% and
21.5%, respectively.3.4. Multivariate analysisIn multiple variable analysis, more than four cycles of
chemotherapy and complete clinical tumor response after
treatment were significant predictors of survival ( p ¼ 0.0244
and p ¼ 0.0039, respectively; Table 4).
4. Discussion
Five to seven beam portals, according to the specific shape
of the CTV, were chosen. This portal number was in agree-
ment with other values in the published literature.11,12 Using
IMRT in our study, the conformal index was 0.8, which
showed good dose conformity for CTV. The calculated HI ofTable 4
Multivariate analysis (n ¼ 39).
Variables Interpretation Full model
Hazard
ratio
95% CI p
Age Every 1-y increment 1.010 (0.979e1.043) 0.5246
Stage IIIA vs. <IIIA 1.157 (0.427e3.138) 0.7740
CT cycles 4 vs. <4 0.314 (0.115e0.861) 0.0244
Tumor length 8 vs. <8 0.981 (0.328e2.938) 0.9730
Tumor location Cervical and Tu
vs. Tm and Tl
0.881 (0.333e2.329) 0.7987
RT dose (cGy) >5040 vs. 5040 2.164 (0.780e6.007) 0.1384
Response non-CR vs. CR 4.757 (1.649e13.724) 0.0039
CI ¼ confidence interval; CR ¼ complete response; CT ¼ chemotherapy;
RT ¼ radiotherapy; Tl ¼ lower thoracic esophageal tumor; Tm ¼ middle
thoracic esophageal tumor; Tu ¼ upper thoracic esophageal tumor.0.9 in our study also represented a good high-dose homoge-
neity to the target.
The IMRT treatment planning system is widely used in
many malignancies, such as malignancies of the head and
neck, lung, and prostate, as well as in gynecological malig-
nancies. IMRT uses nonuniform radiation beams to deliver a
maximum delivery dose to the PTV and to minimize the ra-
diation dose to the normal tissue outside the target. It allows
not only better dose conformity and homogeneity but also an
equivalent local control rate compared with conventional
radiotherapy.
The feasibility of IMRT in esophageal cancer has also been
demonstrated with homogeneity of target volume dose and
decreased radiation dose to the organs at risk.13 Retrospective
studies comparing 3D conformal versus IMRT for patients
with esophageal cancer showed superior dose conformity and
homogeneity with IMRT and reduction of radiation dose to
normal organs (the lungs and heart).11 Our previous study also
demonstrated the practicality of the use of IMRT in post-
operative esophageal cancer patients, which showed a good
coverage of the target and high-dose homogeneity while
decreasing doses to normal tissues (the lung, heart, and spinal
cord).7
The total lung V20 and the mean lung dose are the most
common parameters in predicting the incidence of radiation
pneumonitis. The incidence of pneumonitis decreased with the
use of IMRT compared with 3D-CRT.11,14 In our study, the
mean doses and the average V20 of the total lungs were
1313.7 cGy and 23.4%, respectively. Compared with our
previous study, the total lung V20 was higher, although it did
not exceed the dose constraints.7 This increased the proportion
of total lung V20 mainly because of advanced stage and bulky
tumor mass.
In previous studies, the older radiotherapy technique of
two-dimensional conformal chemoradiotherapy was
frequently used. Based on RTOG criteria, the RTOG 85-01
trial showed that 48% of cases had  Grade 3 hematologic
toxicities and 33% had  Grade 3 nonhematologic toxicities
(the lung and esophagus).3 In the INT-0123 dose comparison
trial, 71% of patients had  Grade 3 acute toxicities and 37%
of patients had  Grade 3 late toxicities in the standard-dose
group.5 An increased cumulative incidence of cardiac-related
death in the 3D-CRT group compared with that in the IMRT
group was also reported.15 The treatment-related toxicities in
our study were fewer than that those reported in previous
studies, which showed that 43.6% of patients had  Grade 3
hematologic toxicity and 2.56% had  Grade 3 non-
hematologic toxicities.
In our study, the main cause of death was pneumonia (11/
32, 34.4%), and the relationship between the radiation pneu-
monitis and pneumonia was reviewed. Six of the 11 patients
had pneumonia patches in the radiation beam pathway and
radiation pneumonitis complicated with pneumonia cannot be
ruled out. Four patients had pneumonia patches out of the
radiation beam pathway. One of the patients did not complete
radiotherapy and was lost to follow-up without further imag-
ing study.
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the six patients, four had in-field failure and received a ra-
diation dose between 50 Gy and 50.4 Gy. The pretreatment
tumor locations were as follows: two upper thoracic, two
middle thoracic, one cervical, and one lower thoracic. A
report published in 2012 by the MD Anderson Cancer
Center found that the most common failure pattern after
definite chemoradiotherapy was GTV failure, with an
increased incidence associated with tumor status (T3/T4)
and tumor size (> 8 cm).16 Of the six patients who had
locoregional recurrence in our study, five had clinical T3
status and one had T1. Only one patient had a tumor size of
8 cm, and the mean tumor size of the six patients was
5.95 cm.
A meta-analysis published in 2012 reported a 2-year overall
survival rate between 35% and 58% after definite chemo-
radiotherapy.17 In our study, the 2- and 3-year survival rates
were 30% and 28%, respectively. These decreased survival
rates might be due to more locally advanced stage (> Stage
IIIA, 74.4%) and poor performance status (Eastern Coopera-
tive Oncology Group performance status ¼ 2, 87.2%). In the
multivariate analysis, more than four cycles of chemotherapy
and complete clinical tumor response played a statistically
significant role in prediction of better survival.
In our study, the overall response rate was 84.6% using the
conventional concurrent chemotherapy regimen with cisplatin
and 5-FU. The response rate was better than in other published
studies.18,19 The conventional chemotherapy regimen com-
bined with radiotherapy still appears to be effective in the
treatment of esophageal cancer. However, as surgical inter-
vention was not a component of the treatment modalities in
our study, no definite evidence for pathologic CR could be
evaluated.
A novel radiotherapy technique called “volumetric modu-
lated arc therapy” (VMAT) is a more sophisticated form of
IMRT and potentially offers greater sparing of normal tissues
and a shorter delivery time. Recent studies showed equivalent
or superior dose distribution but a significantly decreased dose
to organs at risk in VMAT compared with standard step-and-
shoot IMRT in esophageal cancer.20,21 However, VMAT has
the disadvantage of delivering lower doses to a greater volume
of the surrounding normal tissues. Long-term follow-up data
are still needed to demonstrate whether or not VMAT in-
creases late toxicities.
There were several limitations in our study, which included
the use of retrospective data, a small sample size, and possible
selection bias. However, our study demonstrated that CCRT
using the IMRT technique for treating locally advanced
unresectable esophageal cancer is feasible, with better con-
formity of target volume and improved sparing of organs at
risk.
In conclusion, for locally advanced unresectable esopha-
geal cancer, CCRT using the IMRT technique provides better
conformity of target volume as well as improved sparing of
organs at risk. In addition, more than four cycles of chemo-
therapy and complete clinical tumor response after treatment
were significant predictors of survival.References
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